# US 2002/0055651 A1 · Beta2-adrenergic receptor agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0055651 A1
- Document ID: US20020055651A1
- Status: Published application
- Kind: A1
- Application number: 09/934,982
- Filed: 2001-08-21
- Published: 2002-05-09
- Earliest claimed: 1999-06-02
- Assignees: Theravance, Inc.
- Inventors: Edmund J. Moran; John H. Griffin; Seok-Ki Choi
- Web page: https://patentgrep.com/patent/US20020055651A1

## CPC

- C07C 215/60: the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07C 2601/14: The ring being saturated
- C40B 40/00: Libraries per se, e.g. arrays, mixtures
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

## Claims

### Claim 1

A multibinding compound of Formula (I):
(L)p(X)q (I)
wherein:
p is an integer of from 2 to 10;
q is an integer of from 1 to 20;
X is a linker; and
L is a ligand wherein:
one of the ligands, L, is selected from a compound of formula (a):
48
wherein:
Ar1 and Ar2 are independently selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl wherein each of said Ar1 and Ar2 substituent optionally links the ligand to a linker;
R1 is selected from the group consisting of hydrogen, alkyl and substituted alkyl, or R1 is a covalent bond linking the ligand to a linker;
R2 is selected from the group consisting of hydrogen, alkyl, aralkyl, acyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl, or R2 is a covalent bond linking the ligand to a linker;
W is a covalent bond linking the —NR2— group to Ar2, alkylene or substituted alkylene wherein one or more of the carbon atoms in said alkylene or substituted alkylene group which is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and further wherein said alkylene or substituted alkylene group optionally links the ligand to a linker provided that at least one of Ar1, Ar2, R1, R2, or W links the ligand to a linker; and
the other ligands are independently selected from a compound of formula (b):
-Q-Ar3 (b)
wherein:
Ar3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl;
Q, which links the other ligand to the linker, is selected from the group consisting of a covalent bond, alkylene or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—. —S(O)n— (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O— P(O)O—; and
pharmaceutically acceptable salts thereof provided that:
(i) when the multibinding compound of Formula (I) is a compound of formula:
49
where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alkylene-O—:
(ii) when the multibinding compound of Formula (I) is a compound of formula:
50
where Ar1 is 4-hydroxy-2-methylphenyl, Ar2 is aryl, Ar3 is aryl or heterocyclyl, W is ethylene, Q is a covalent bond, R1 is alkyl then the linker X is not linked to the Ar3 group through an oxygen atom; and
(iii) when the multibinding compound of Formula (I) is a compound of formula:
51
where Ar1, Ar2, Ar3, R1, R2 are as defined above, W is alkylene, and Q is a covalent bond, then X is not -alkylene-O—.

### Claim 2 (depends on 2)

The multibinding compound of claim 2 wherein q is less than p

### Claim 3 (depends on 2)

The multibinding compound of claim 2 wherein each linker, X, in the multibinding compound of Formula (I) independently has the formula:
—Xa-Z-(Ya-Z)m-Xa—
wherein
m is an integer of from 0 to 20;
Xa at each separate occurrence is selected from the group consisting of —O—, —S—, —NR—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)NR—, —NRC(O)—, C(S), —C(S)O—, —C(S)NR—, —NRC(S)—, or a covalent bond where R is as defined below;
Z at each separate occurrence is selected from the group consisting of alkylene, substituted alkylene, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, heteroarylene, heterocyclene, or a covalent bond;
each Ya at each separate occurrence is selected from the group consisting of —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—, —S(O)n—, —C(O)NR′—, —NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—, —C(═NR)—NR′—, —NR′—C(═NR)—, —OC(O)—NR′—, —NR′—C(O)—O—, —N═C(Xa)—NR′—, —NR′—C(Xa)═N—, —P(O)(OR′)—O—, —O—P(O)(OR′)—, —S(O)nCR′R″—, —S(O)n—NR′—, —NR′—S(O)n—, —S—S—, and a covalent bond; where n is 0, 1 or 2; R, R′ and R″ at each separate occurrence are selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic, and Xa is as defined above.

### Claim 4

A bivalent multibinding compound of Formula (II):
52
wherein:
Ar1 is:
(a) a phenyl ring of formula (c):
53
wherein:
R4 is hydrogen, alkyl, halo, or alkoxy;
R5 is hydrogen, hydroxy, halo, halo, amino, or —NHSO2Ra where Ra is alkyl;
R6 is hydrogen, halo, hydroxy, alkoxy, substituted alkyl, sulfonylamino, aminoacyl, or acylamino;
W is a bond linking the —NR2— group to Ar2, an alkylene or substituted alkylene chain wherein one or more of the carbon atoms in the alkylene or substituted alkylene group are optionally replaced by —O—;
Ar2 is phenyl wherein the W and the X groups are attached at the 1,2-, 1,3, and 1,4 positions of the phenyl ring; cyclohexyl optionally substituted with methyl and wherein the W and the X groups are attached at the 1,3, and 1,4 positions of the cyclohexyl ring; or piperazine wherein the W and the X groups are attached at the 1,4 positions of the piperazine ring:
X is a linker;
Q is a covalent bond, alkylene, or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a heteroatom such as —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and links the ligand to a linker; and
Ar3 is either:
(i) a phenyl ring of formula (c) as defined above; or
(ii) a phenyl ring of formula (d):
54
wherein:
R7 is hydrogen, alkyl, alkenyl, substituted alkyl, halo, alkoxy, substituted alkoxy, hydroxy, aminoacyl, or heteroaryl; and
R8 is hydrogen, halo, alkoxy, substituted alkoxy, acylamino; or
(iii) naphthyl, pyridyl, benzimidazol-1-yl, indolyl, 2-cyanoindolyl, carbazolyl, 4-methsyindanyl, 5-(CH3CO2CH2O—)-1,2,3,4-tetrahydronaphthyl, 1H-2-oxoindole, 2,3,4-trihydrothianaphthalene, or 4-oxo-2,3-dihydrothianapthalene; and
pharmaceutically acceptable salts thereof provided that:
when the multibinding compound of Formula (I) is a compound of formula:
55
where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alklylene-O—.

### Claim 5 (depends on 4)

The bivalent multibinding compound of claim 4, wherein:
X is —O—, —O-alkylene, —O-(arylene)-NH-(substituted alkylene), —O-(alkylene)-O-(arylene)-(alkylene)-O-(alkylene)-NH-(substituted alkylene), —O-(alkylene)-O-(arylene)-, -(alkylene)-(cycloalkylene)-NH-(substituted alkylene); and
Q is a covalent bond.

### Claim 6 (depends on 5)

The bivalent multibinding compound of claim 5, wherein:
Ar1 is:
(a) a phenyl ring of formula (c):
56
wherein:
R4 is hydrogen, methyl, fluoro, chloro, methoxy;
R5 is hydrogen, hydroxy, fluoro, chloro, amino, —NHSO2CH3;
R6 is hydrogen, chloro, fluoro, hydroxy, methoxy, hydroxymethyl, —CH2SO2CH3, —NHSO2CH3, —NHCHO, —CONH2, —NHCONH2;
Ar2 is phenyl wherein the W and the X groups are attached at the 1,4 position of the phenyl ring; and
Ar3 is either:
(i) a phenyl ring of formula (c) as defined above; or
(ii) a phenyl ring of formula (d):
57
wherein:
R7 is hydrogen, methyl, propen-2-yl, fluoro, chloro, methoxy, —CH2CO2Me, hydroxy, —CH2CONH2, —NHCOCH3, imidazol-1-yl, or 1-methyl-4-trifluoromethyl-imidazol-2-yl; and
R8 is hydrogen, fluoro, chloro, methoxy, —CH2CO,Me, or —CONH2 or
(iii) naphthyl, pyridyl, benzimidazol-1-yl, indolyl, 2-cyanoindolyl, carbazolyl, 4-methylindanyl, 5-(CH3CO2CH2O—)-1,2,3,4-tetrahydronaphthyl, 1H-2-oxoindole, 2,3,4-trihydrothianaphthalene, or 4-oxo-2,3-dihydrothianapthalene.

### Claim 7 (depends on 6)

The bivalent multibinding compound of claim 6 wherein:
Ar1 is phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 3,4-dichlorophenyl, 2-chloro-3,4-dihydroxyphenyl, 2-fluoro-3,4-dihydroxyphenyl, 2-chloro-3,5-dihydroxyphenyl, 2-fluoro-3,5-dihydroxyphenyl, 4-hydroxy-3-methoxyphenyl, 4-hydroxy-3-hydroxymethylphenyl, 4-hydroxy-3-(HCONH—)phenyl, 4-hydroxy-3-(NH2CO—)phenyl, 3-chlorophenyl, 2,5-dimethoxyphenyl, 4-(CH3SO2NH—)-phenyl, 4-hydroxy-3-(CH3SO2CH2—)phenyl, 4-hydroxy-3-(CH3SO2O2NH—)phenyl, 4-hydroxy-3-(NH2CONH—)phenyl, or 3,5-dichloro-4-aminophenyl;
W is a bond, methylene, ethylene, propylene, —(CH2)6—O—(CH2)—, —(CH2)6—O—, or —CH2CH(OH)CH2—O—;
X is —O—; —O—(CH2)4—, —O-(1,4-phenylene)-NH—CH2—CH(OH)—; —O—(CH2)10—O-(1,4-phenylene)-(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—; —O—(CH2)6—O-(1,4-phenylene)-(CH2)3—O—(CH2)5—NH—CH2—CH(OH)—; —O—(CH2)6—O-(1,4-phenylene )-; —CH2-(1,4-cyclohexyl)-NH—CH2—CH(OH)—; and
Ar3 is:
58

### Claim 8 (depends on 4)

The bivalent multibinding compound of claim 4, wherein:
X is a covalent bond; and
Q is a substituted alkylene group wherein one or more of the carbon atoms in said substituted alkylene group is optionally replaced by a heteroatom such as —NRa— (where Ra is hydrogen, alkyl, or acyl) or —O—.

### Claim 9 (depends on 8)

The bivalent multibinding compound of claim 8, wherein:
Ar1 is:
(a) a phenyl ring of formula (c):
59
wherein:
R4 is hydrogen, methyl, fluoro, chloro, methoxy;
R5 is hydrogen, hydroxy, fluoro, chloro, amino, —NHSO2CH3; and
R6 is hydrogen, chloro, fluoro, hydroxy, methoxy, hydroxymethyl, —CH2SO2CH3, —NHSO2CH3, —NHCHO, —CONH2, —NHCONH2;
Ar2 is phenyl wherein the W and the X groups are attached at the 1,4 position of the phenyl ring; and
Ar3 is either:
(i) a phenyl ring of formula (c) as defined above; or
(ii) a phenyl ring of formula (d):
60
wherein:
R7 is hydrogen, methyl, propen-2-yl, fluoro, chloro, methoxy, —CH2CO2Me, hydroxy, —CH2CONH2, —NHCOCH3, imidazol-1-yl, or 1-methyl-4-trifluoromethyl-imidazol-2-yl; and
R8 is hydrogen, fluoro, chloro, methoxy, —CH2CO2Me, or —CONH2 or
(iii) naphthyl, pyridyl, benzimidazol-1-yl, indolyl, 2-cyanoindolyl, carbazolyl, 4-methylindanyl, 5-(CH3CO2CH2O—)-1,2,3,4-tetrahydronaphthyl, 1H-2-oxoindole, 2,3,4-trihydrothianaphthalene, or 4-oxo-2,3-dihydrothianapthalene.

### Claim 10 (depends on 9)

The bivalent multibinding compound of claim 9 wherein:
Ar1 is phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 3,4-dichlorophenyl, 2-chloro-3,4-dihydroxyphenyl, 2-fluoro-3,4-dihydroxyphenyl, 2-chloro-3,5-dihydroxyphenyl, 2-fluoro-3,5-dihydroxyphenyl, 4-hydroxy-3-methoxyphenyl, 4-hydroxy-3-hydroxymethylphenyl, 4-hydroxy-3-(HCONH—)phenyl, 4-hydroxy-3-(NH2CO—)phenyl, 3-chlorophenyl, 2,5-dimethoxyphenyl, 4-(CH3SO2NH—)-phenyl, 4-hydroxy-3-(CH3SO2CH2—)phenyl, 4-hydroxy-3-(CH3SO2NH—)phenyl, 4-hydroxy-3-(NH2CONH—)phenyl, or 3,5-dichloro-4-aminophenyl;
W is a bond, methylene, ethylene, propylene, —(CH2)6—O—(CH2)3—, —(CH2)6—O—, or —CH2CH(OH)CH2—O—;
Q is —NH—CH2—CH(OH)—; —NH—CH(CH2OH)—; —CH2—NH—CH2—CH(OH)—; —C(CH3)2—NH—CH2—CH(OH)—; —(CH2)3—NH—CH2—CH(OH)—; —(CH2)3—O—(CH2)6—NH—CH2—CH(OH)—; —(CH2)2—NH—CH2—CH(OH)—; or —O—(CH2)—CH(OH)—CH2—NH—CH2—CH(OH)—; and
Ar3 is:
61

### Claim 11 (depends on 10)

The multibinding compound of claim 10 wherein:
Ar1 and Ar3 are phenyl;
W is ethylene; and
Q is —NH—CH2-*CH(OH)— (where * is R or S stereochemistry);

### Claim 12 (depends on 9)

The bivalent multibinding compound of claim 9 wherein:
Ar1 is phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 3,4-dichlorophenyl, 2-chloro-3,4-dihydroxyphenyl, 2-fluoro-3,4-dihydroxyphenyl, 2-chloro-3,5-dihydroxyphenyl, 2-fluoro-3,5-dihydroxyphenyl, 4-hydroxy-3-methoxyphenyl, 4-hydroxy-3-hydroxymethylphenyl, 4-hydroxy-3-(HCONH—)phenyl, 4-hydroxy-3-(NH2CO—)phenyl, 3-chlorophenyl, 2,5-dimethoxyphenyl, 4-(CH3SO2NH—)-phenyl, 4-hydroxy-3-(CH3SO2CH2—)phenyl, 4-hydroxy-3-(CH3SO2NH—)phenyl, 4-hydroxy-3-(NH2CONH—)phenyl, or 3,5-dichloro-4-aminophenyl;
W is a bond, methylene, ethylene, propylene, —(CH2)6—O—(CH2)3—, —(CH2)6—O—, or —CH2CH(OH)CH2—O—;
Q is —NH—CH3—CH(OH)—CH2—O—; and
Ar3 is:
62

### Claim 13

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a multibinding compound of Formula (I):
(L)p(X)q (I)
wherein:
p is an integer of from 2 to 10;
q is an integer of from 1 to 20;
X is a linker; and
L is a ligand wherein:
one of the ligands, L, is selected from a compound of formula (a):
63
wherein:
Ar1 and Ar2 are independently selected from the group consisting of aryl, heteroaryl, cycloalkyl substituted cycloalkyl, and heterocyclyl wherein each of said Ar1 and Ar2 substituent optionally links the ligand to a linker;
R1 is selected from the group consisting of hydrogen, alkyl and substituted alkyl, or R1 is a covalent bond linking the ligand to a linker;
R2 is selected from the group consisting of hydrogen, alkyl, aralkyl, acyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl, or R2 is a covalent bond linking the ligand to a linker;
W is a covalent bond linking the —NR2— group to Ar2, alkylene or substituted alkylene wherein one or more of the carbon atoms in said alkylene or substituted alkylene group which is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and further wherein said alkylene or substituted alkylene group optionally links the ligand to a linker provided that at least one of Ar1, Ar2, R1, R2, or W links the ligand to a linker; and
the other ligands are independently selected from a compound of formula (b):
-Q-Ar3 (b)
wherein:
Ar3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl;
Q, which links the other ligand to the linker, is selected from the group consisting of a covalent bond, alkylene, or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n— (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O—; and
pharmaceutically acceptable salts thereof provided that:
(i) when the multibinding compound of Formula (I) is a compound of formula:
64
where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alkylene-O—;
(ii) when the multibinding compound of Formula (I) is a compound of formula:
65
where Ar1 is 4-hydroxy-2-methylphenyl, Ar2 is aryl, Ar3 is aryl or heterocyclyl, W is ethylene, Q is a covalent bond, R1 is alkyl, then the linker X is not linked to the Ar3 group through an oxygen atom; and
(iii) when the multibinding compound of Formula (I) is a compound of formula:
66
where Ar1, Ar2, Ar3, R1, R2 are as defined above, W is alkylene, and Q is a covalent bond, then X is not -alkylene-O—.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 wherein q is less than p.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14 wherein each linker independently has the formula:
—Xa-Z-(Ya-Z)m—Xa—
wherein
m is an integer of from 0 to 20;
Xa at each separate occurrence is selected from the group consisting of —O—, —S—, —NR—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)NR—, —NRC(O)—, C(S), —C(S)O—, —C(S)NR—, —NRC(S)—, or a covalent bond where R is as defined below;
Z at each separate occurrence is selected from the group consisting of alkylene, substituted alkylene, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, heteroarylene, heterocyclene, or a covalent bond;
each Ya at each separate occurrence is selected from the group consisting of —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—, —S(O)n—, —C(O)NR′, —NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—, —OC(O)—NR′—, —NR′—C(O)—O—, —N═C(Xa)—NR′—, —NR′—C(Xa)═N—, —P(O)(OR′)—O—, —O—P(O)(OR′)—, —S(O)nCR′R″—, —S(O)n—NR′—, —NR′—S(O)n—, —S—S—, and a covalent bond; where n is 0, 1 or 2; R, R′ and R″ at each separate occurrence are selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic, and Xa is as defined above.

### Claim 16 (depends on 7)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a multibinding compound of claim 7.

### Claim 17 (depends on 10)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a multibinding compound of claim 10.

### Claim 18

A method for treating diseases mediated by a β2 adrenergic receptor in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a multibinding compound of Formula (I):
(L)p(X)q
wherein:
p is an integer of from 2 to 10;
q is an integer of from 1 to 20;
X is a linker; and
L is a ligand wherein:
one of the ligands, L, is selected from a compound of formula (a):
67
wherein:
Ar1 and Ar2 are independently selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl wherein each of said Ar1 and Ar2 substituent optionally links the ligand to a linker;
R1 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl, or R1 is a covalent bond linking the ligand to a linker;
R2 is selected from the group consisting of hydrogen, alkyl, aralkyl, acyl, substituted alkyl, cycloalkyl, and substituted cycloalkyl, or R2 is a covalent bond linking the ligand to a linker;
W is a covalent bond linking the —NR2— group to Ar2, alkylene or substituted alkylene wherein one or more of the carbon atoms in said alkylene or substituted alkylene group which is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O— and further wherein said alkylene or substituted alkylene group optionally links the ligand to a linker provided that at least one of Ar1, Ar2, R1, R2, or W links the ligand to a linker; and
the other ligands are independently selected from a compound of formula (b):
-Q-Ar3 (b)
wherein:
Ar3 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, substituted cycloalkyl, and heterocyclyl;
Q, which links the other ligand to the linker, is selected from the group consisting of a covalent bond, alkylene, or a substituted alkylene group wherein one or more of the carbon atoms in said alkylene or substituted alkylene group is optionally replaced by a substituent selected from —NRa— (where Ra is hydrogen, alkyl, acyl, or a covalent bond linking the ligand to a linker), —O—, —S(O)n— (where n is an integer of from 0 to 2), —CO—, —PRb— (where Rb is alkyl), —P(O)2—, and —O—P(O)O—; and
pharmaceutically acceptable salts thereof provided that:
(i) when the multibinding compound of Formula (I) is a compound of formula:
68
where Ar1 and Ar3 are aryl, then W and X both are not alkylene or alkylene-O—;
(ii) when the multibinding compound of Formula (I) is a compound of formula:
69
where Ar1 is 4-hydroxy-2-methylphenyl, Ar2 is aryl, Ar3 is aryl or heterocyclyl, W is ethylene, Q is a covalent bond, R1 is alkyl, then the linker X is not linked to the Ar3 group through an oxygen atom; and
(iii) when the multibinding compound of Formula (I) is a compound of formula:
70
where Ar1, Ar2, Ar3, R1, R2 are as defined above, W is alkylene, and Q is a covalent bond, then X is not -alkylene-O—.

### Claim 19 (depends on 7)

A method for treating diseases mediated by a β2 adrenergic receptor in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a multibinding compound of claim 7.

### Claim 20 (depends on 10)

A method for treating diseases mediated by a β2 adrenergic receptor in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a multibinding compound of claim 10.

### Claim 21 (depends on 20)

The method of claim 20 wherein the disease is a respiratory disease.

### Claim 22 (depends on 21)

The method of claim 21 wherein the disease is asthma.

### Claim 23

A method for identifying multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor which method comprises:
(a) identifying a ligand or a mixture of ligands wherein each ligand contains at least one reactive functionality;
(b) identifying a library of linkers wherein each linker in said library comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand;
(c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the ligand or mixture of ligands identified in (a) with the library of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands; and
(d) assaying the multimeric ligand compounds produced in the library prepared in (c) above to identify multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor.

### Claim 24

A method for identifying multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor which method comprises:
(a) identifying a library of ligands wherein each ligand contains at least one reactive functionality;
(b) identifying a linker or mixture of linkers wherein each linker comprises at least two functional groups having complementary reactivity to at least one of the reactive function al groups of the ligand;
(c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the library of ligands identified in (a) with the linker or mixture of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands; and
(d) assaying the multimeric ligand compounds produced in the library prepared in (c) above to identify multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor.

### Claim 25 (depends on 23, 24)

The method according to claim 23 or 24 wherein the preparation of the multimeric ligand compound library is achieved by either the sequential or concurrent combination of the two or more stoichiometric equivalents of the ligands identified in (a) with the linkers identified in (b).

### Claim 26 (depends on 25)

The method according to claim 25 wherein the multimeric ligand compounds comprising the multimeric ligand compound library are dimeric.

### Claim 27 (depends on 26)

The method according to claim 26 wherein the dimeric ligand compounds comprising the dimeric ligand compound library are heterodimeric.

### Claim 28 (depends on 27)

The method according to claim 27 wherein the heterodimeric ligand compound library is prepared by sequential addition of a first and second ligand.

### Claim 29 (depends on 23, 24)

The method according to claim 23 or 24 wherein, prior to procedure (d), each member of the multimeric ligand compound library is isolated from the library.

### Claim 30 (depends on 29)

The method according to claim 29 wherein each member of the library is isolated by preparative liquid chromatography mass spectrometry (LCMS).

### Claim 31 (depends on 23, 24)

The method according to claim 23 or claim 24 wherein the linker or linkers employed are selected from the group comprising flexible linkers, rigid linkers, hydrophobic linkers, hydrophilic linkers, linkers of different geometry, acidic linkers, basic linkers, linkers of different polarization and amphiphilic linkers.

### Claim 32 (depends on 31)

The method according to claim 31 wherein the linkers comprise linkers of different chain length and/or having different complementary reactive groups.

### Claim 33 (depends on 32)

The method according to claim 32 wherein the linkers are selected to have different linker lengths ranging from about 1 to 100 Å.

### Claim 34 (depends on 23, 24)

The method according to claim 23 or 24 wherein the ligand or mixture of ligands is selected to have reactive functionality at different sites on said ligands.

### Claim 35 (depends on 34)

The method according to claim 34 wherein said reactive functionality is selected from the group consisting of carboxylic acids, carboxylic acid halides, carboxyl esters, amines, halides, pseudohalides, isocyanates, vinyl unsaturation, ketones, aldehydes, thiols, alcohols, anhydrides, boronates, and precursors thereof wherein the reactive functionality on the ligand is selected to be complementary to at least one of the reactive groups on the linker so that a covalent linkage can be formed between the linker and the ligand.

### Claim 36 (depends on 23, 24)

The method according to claim 23 or claim 24 wherein the multimeric ligand compound library comprises homomeric ligand compounds.

### Claim 37 (depends on 23, 24)

The method according to claim 23 or claim 24 wherein the multimeric ligand compound library comprises heteromeric ligand compounds.

### Claim 38

A library of multimeric ligand compounds which may possess multivalent properties for β2 adrenergic receptor which library is prepared by the method comprising
(a) identifying a ligand or a mixture of ligands wherein each ligand contains at least one reactive functionality;
(b) identifying a library of linkers wherein each linker in said library comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand; and
(c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the ligand or mixture of ligands identified in (a) with the library of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands.

### Claim 39

A library of multimeric ligand compounds which may possess multivalent properties for β2 adrenergic receptor which library is prepared by the method comprising:
(a) identifying a library of ligands wherein each ligand contains at least one reactive functionality;
(b) identifying a linker or mixture of linkers wherein each linker comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand; and
(c) preparing a multimeric ligand compound library by combining at least two stoichiometric equivalents of the library of ligands identified in (a) with the linker or mixture of linkers identified in (b) under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands.

### Claim 40 (depends on 38, 39)

The library according to claim 38 or claim 39 wherein the linker or linkers employed are selected from the group comprising flexible linkers rigid linkers, hydrophobic linkers, hydrophilic linkers, linkers of different geometry, acidic linkers, basic linkers, linkers of different polarization and/or polarizability, and amphiphilic linkers.

### Claim 41 (depends on 40)

The library according to claim 40 wherein the linkers comprise linkers of different chain length and/or having different complementary reactive groups.

### Claim 42 (depends on 41)

The library according to claim 41 wherein the linkers are selected to have different linker lengths ranging from about 2 to 100 Å.

### Claim 43 (depends on 38, 39)

The library according to claim 38 or 39 wherein the ligand or mixture of ligands is selected to have reactive functionality at different sites on said ligands.

### Claim 44 (depends on 43)

The library according to claim 43 wherein said reactive functionality is selected from the group consisting of carboxylic acids carboxylic acid halides, carboxyl esters, amines halides, pseudohalides, isocyanates, vinyl unsaturation, ketones, aldehydes, thiols, alcohols, anhydrides, boronates, and precursors thereof wherein the reactive functionality on the ligand is selected to be complementary to at least one of the reactive groups on the linker so that a covalent linkage can be formed between the linker and the ligand.

### Claim 45 (depends on 38, 39)

The library according to claim 38 or claim 39 wherein the multimeric ligand compound library comprises homomeric ligand compounds.

### Claim 46 (depends on 38, 39)

The library according to claim 38 or claim 39 wherein the multimeric ligand compound library comprises heteromeric ligand compounds.

### Claim 47

An iterative method for identifying multimeric ligand compounds possessing multibinding properties for β2 adrenergic receptor which method comprises:
(a) preparing a first collection or iteration of multimeric compounds which is prepared by contacting at least two stoichiometric equivalents of the ligand or mixture of ligands which target a receptor with a linker or mixture of linkers wherein said ligand or mixture of ligands comprises at least one reactive functionality and said linker or mixture of linkers comprises at least two functional groups having complementary reactivity to at least one of the reactive functional groups of the ligand wherein said contacting is conducted under conditions wherein the complementary functional groups react to form a covalent linkage between said linker and at least two of said ligands,
(b) assaying said first collection or iteration of multimeric compounds to assess which if any of said multimeric compounds possess multibinding properties for β2 adrenergic receptor;
(c) repeating the process of (a) and (b) above until at least one multimeric compound is found to possess multibinding properties for β2 adrenergic receptor;
(d) evaluating what molecular constraints imparted multibinding properties to the multimeric compound or compounds found in the first iteration recited in (a)-(c) above;
(e) creating a second collection or iteration of multimeric compounds which elaborates upon the particular molecular constraints imparting multibinding properties for β2 adrenergic receptor to the multimeric compound or compounds found in said first iteration;
(f) evaluating what molecular constraints imparted enhanced multibinding properties to the multimeric compound or compounds found in the second collection or iteration recited in (e) above;
(g) optionally repeating steps (e) and (f) to further elaborate upon said molecular constraints.

### Claim 48 (depends on 47)

The method according to claim 47 wherein steps (e) and (f) are repeated from 2-50 times.

### Claim 49 (depends on 48)

The method according to claim 48 wherein steps (e) and (f) are repeated from 5-50 times.
